Summit Therapeutics Inc (SMMT) concluded trading on Wednesday at a closing price of $19.54, with 4.73 million shares of worth about $92.43 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 394.68% during that period and on October 02, 2024 the price saw a loss of about -2.79%. Currently the company’s common shares owned by public are about 701.66M shares, out of which, 102.27M shares are available for trading.
Stock saw a price change of -13.69% in past 5 days and over the past one month there was a price change of 55.08%. Year-to-date (YTD), SMMT shares are showing a performance of 648.66% which increased to 1003.95% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.64 but also hit the highest price of $33.89 during that period. The average intraday trading volume for Summit Therapeutics Inc shares is 4.80 million. The stock is currently trading -11.78% below its 20-day simple moving average (SMA20), while that difference is up 23.98% for SMA50 and it goes to 156.07% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Summit Therapeutics Inc (NASDAQ: SMMT) currently have 701.66M outstanding shares and institutions hold larger chunk of about 10.00% of that.
The stock has a current market capitalization of $14.15B and its 3Y-monthly beta is at -0.93. It has posted earnings per share of -$0.23 in the same period. It has Quick Ratio of 2.35 while making debt-to-equity ratio of 0.56. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SMMT, volatility over the week remained 8.77% while standing at 13.78% over the month.
Stock’s fiscal year EPS is expected to rise by 72.30% while it is estimated to decrease by -10.69% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on September 27, 2024 offering a Neutral rating for the stock and assigned a target price range of between $19 and $23 to it. Coverage by H.C. Wainwright stated Summit Therapeutics Inc (SMMT) stock as a Buy in their note to investors on August 12, 2024, suggesting a price target of $16 for the stock. On May 07, 2024, Citigroup Initiated their recommendations, while on March 26, 2024, Stifel Initiated their ratings for the stock with a price target of $8. Stock get a Neutral rating from Janney on June 28, 2018.
